PIA
ICPT

Piedmont Investment Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Piedmont Investment Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-380
Closed -$32K – 2465
2018
Q2 		$32K Buy
+380
New +$27.8K ﹤0.01% 1451

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Piedmont Investment Advisors's ICPT Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2018, closing a stake of 380 shares — an estimated $32K sold.

Piedmont Investment Advisors first reported a position in ICPT in Q2 2018 and held it in 1 quarter. The position peaked at $32K in Q2 2018. 175 funds tracked by Wall St. Rank hold ICPT as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 380 Intercept Pharmaceuticals, Inc. shares in Q3 2018, an estimated $32K.
  • Piedmont Investment Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Intercept Pharmaceuticals, Inc. position peaked at $32K in Q2 2018.
  • 175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.